The SAFFRON and SANOVO Phase III readouts (savolitinib) in H2 2026 are the next major binary catalysts that could support global filings. Additionally, sovleplenib NDA decisions for ITP and wAIHA in China are pending. The company's strong cash position and growing China commercial franchise provide a solid floor, while the early-stage ATTC platform adds optionality. Monitor partner discussions for out-licensing of ATTC assets.
Price Chart
Executive Summary
HUTCHMED reported H1 2026 results with total revenue essentially flat at $278.3M (vs $277.7M in H1 2025) but a strong 23% increase in Oncology/Immunology marketed product revenue to $121.4M, driven by ELUNATE (+41%), SULANDA (+45%), and FRUZAQLA ex-US (+70%). Net income attributable to HUTCHMED was $15.9M, down sharply from $455.0M in H1 2025 which included a $416.3M gain on the SHPL divestment. The company reiterated full-year 2026 Oncology/Immunology revenue guidance of $330M-$450M and ended the period with $1.37B in cash. Key pipeline catalysts include expected SAFFRON and SANOVO Phase III readouts in H2 2026 and two sovleplenib NDAs under priority review in China.
Key Facts
- Total revenue H1 2026: $278.3M (flat vs $277.7M H1 2025; -4% actual, +4% CER)
- Oncology/Immunology consolidated revenue: $162.3M, up 13% (10% CER)
- Net income attributable to HUTCHMED: $15.9M ($0.02/share basic EPS vs $0.53 in H1 2025, which included $416.3M SHPL gain)
- Cash & short-term investments: $1.37B as of June 30, 2026
- ELUNATE in-market sales: +41% to $60.8M; SULANDA: +45% to $18.4M
- FRUZAQLA ex-US in-market sales: +70% to $68.9M; approved/launched in 41 countries
- Savolitinib sNDA approved for 3L MET-amplified gastric cancer in China (June 2026)
- Sovleplenib NDAs accepted with priority review for ITP (Feb 2026) and wAIHA (Apr 2026)
- Fanregratinib NDA under priority review for 2L FGFR2-driven ICC; pivotal Phase II data showed 42.5% ORR
- SAFFRON global Phase III (savolitinib) and SANOVO China Phase III topline results expected H2 2026
- TAZVERIK voluntarily withdrawn by Ipsen in March 2026; $8.9M impairment taken
- R&D expenses: $78.8M, up 9% from $72.0M, driven by ATTC global clinical programs
- Full-year 2026 guidance reiterated: Oncology/Immunology revenue $330M-$450M
Financial Impact
Core oncology/immunology revenue growing 13% (10% CER) with strong product momentum; net income down due to prior-year one-time gain; cash position robust at $1.37B; guidance reiterated with midpoint implying H2 pick-up
Risk Factors
- China regulatory and pricing/payer environment remains uncertain; NRDL renewals could pressure margins
- SAFFRON and SANOVO Phase III trials may miss endpoints, delaying global filings for savolitinib
- CEO on leave of absence adds management uncertainty
- TAZVERIK withdrawal signals potential safety or commercial risk in partnered products
- ATTC platform is early-stage (Phase I) with no clinical proof-of-concept yet
- RMB appreciation against USD impacted reported results by ~5% in H1 2026; further FX headwinds possible
- Competition in CRC (FRUZAQLA) and NET (SULANDA) from newer therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-088458 |
| Document: hcm-20260730xex99d2.htm | 0001104659-26-088458 |
| Document: hcm-20260730x6k.htm | 0001104659-26-088458 |
| Document: 0001104659-26-088458-index-headers.html | 0001104659-26-088458 |
| Document: 0001104659-26-088458-index.html | 0001104659-26-088458 |
| Document: 0001104659-26-088458.txt | 0001104659-26-088458 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | 6-K | $14.11 $12.82 | ▼ −9.14% | ▼ −7.99% | $14.31 (+1.42%) |
Aug 31, 2026 4w ago | 6-K | $12.12 $13.88 | ▲ +14.52% | ▲ +14.66% | $14.31 (+18.07%) |
Aug 18, 2026 6w ago | 6-K | $12.64 $12.26 | ▼ −3.01% | ▼ −2.81% | $14.31 (+13.21%) |
Aug 17, 2026 6w ago | 6-K | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Aug 17, 2026 6w ago | Press Release | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Jul 30, 2026 9w ago | 6-K | $10.77 $11.83 | ▲ +9.84% | ▲ +6.22% | $14.31 (+32.87%) |
Jul 2, 2026 13w ago | 6-K | $11.44 $10.98 | ▼ −4.02% | ▼ −4.95% | $14.31 (+25.09%) |
Jun 30, 2026 13w ago | 6-K | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 30, 2026 13w ago | Press Release | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 29, 2026 13w ago | 6-K | $10.71 $11.65 | ▲ +8.78% | ▲ +7.39% | $14.31 (+33.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access